Publications - Page 14 sur 43 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Hypertension pulmonaire (HTP) 31/08/23
Pulmonary hypertension without heart failure causes cardiorenal syndrome in a porcine model.

Orieux A, Samson C, Pieroni L, Drouin S, Dang Van S, Migeon T, Frere P, Brunet D, Buob D, Hadchouel J, Guihaire J, Mercier O, Galichon P.

Sci Rep. 2023 Jun 5;13(1):9130. doi: 10.1038/s41598-023-36124-1.
Hypertension pulmonaire (HTP) 31/08/23
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management.

Delcroix M, de Perrot M, Jaïs X, Jenkins DP, Lang IM, Matsubara H, Meijboom LJ, Quarck R, Simonneau G, Wiedenroth CB, Kim NH.

Lancet Respir Med. 2023 Aug 14:S2213-2600(23)00292-8.
Hypertension pulmonaire (HTP) 31/08/23
[Lung transplantation for severe pulmonary hypertension].

Le Pavec J, Savale L, Prévot G, Montani D, Sitbon O, Fadel E, Humbert M, Mercier O.

Rev Mal Respir. 2023 Mar;40 Suppl 1:e52-e57.
Hypertension pulmonaire (HTP) 31/08/23
Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: A retrospective, observational cohort study in France.

Lamia B, Dallongeville J, Bensimon L, Hakme A, Bénard N, Lévy-Bachelot L, Pouriel M, Sitbon O.

Respir Med Res. 2023 Jun;83:100987.
Hypertension pulmonaire (HTP) 31/08/23
Pulmonary hypertension among preterm infants born at 22 through 32 weeks gestation in France: Prevalence, survival, morbidity and management in the EPIPAGE-2 cohort study.

Breinig S, Ehlinger V, Rozé JC, Storme L, Torchin H, Durrmeyer X, Cambonie G, Delacourt C, Jarreau PH, Berthomieu L, Brissaud O, Benhammou V, Gascoin G, Arnaud C, Ancel PY.

Early Hum Dev. 2023 Aug 3;184:105837.
Pneumopathies interstitielles diffuses (PID) 31/08/23
Interstitial lung disease-associated pulmonary hypertension – what the future holds.

Cottin V, Diesler R, Turquier S, Valenzuela C.

Curr Opin Pulm Med. 2023 Sep 1;29(5):406-415.
Fibrose pulmonaire - FPI 31/08/23
Vascular-Parenchymal Cross-Talk Promotes Lung Fibrosis through BMPR2 Signaling.

Yanagihara T, Tsubouchi K, Zhou Q, Chong M, Otsubo K, Isshiki T, Schupp JC, Sato S, Scallan C, Upagupta C, Revill S, Ayoub A, Chong SG, Dvorkin-Gheva A, Kaminski N, Tikkanen J, Keshavjee S, Paré G, Guignabert C, Ask K, Kolb MRJ.

Am J Respir Crit Care Med. 2023 Jun 1;207(11):1498-1514.
Hypertension pulmonaire (HTP) 31/08/23
New trends in pulmonary hypertension.

Cullivan S, Gaine S, Sitbon O.

Eur Respir Rev. 2023 Feb 21;32(167):220211.
Hypertension pulmonaire (HTP) 31/08/23
AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study.

Gillies H, Niven R, Dake BT, Chakinala MM, Feldman JP, Hill NS, Hoeper MM, Humbert M, McLaughlin VV, Kankam M.

ERJ Open Res. 2023 Mar 13;9(2):00433-2022.
Hypertension pulmonaire (HTP) 31/08/23
Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1.

Mumby S, Perros F, Grynblat J, Manaud G, Papi A, Casolari P, Caramori G, Humbert M, John Wort S, Adcock IM.

Respir Res. 2023 Jul 29;24(1):193.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Pulmonary hypertension without heart failure causes cardiorenal syndrome in a porcine model.

Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management.

[Lung transplantation for severe pulmonary hypertension].

Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: A retrospective, observational cohort study in France.

Pulmonary hypertension among preterm infants born at 22 through 32 weeks gestation in France: Prevalence, survival, morbidity and management in the EPIPAGE-2 cohort study.

Interstitial lung disease-associated pulmonary hypertension – what the future holds.

Vascular-Parenchymal Cross-Talk Promotes Lung Fibrosis through BMPR2 Signaling.

New trends in pulmonary hypertension.

AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study.

Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1.